Novel nomogram for predicting survival in advanced non-small cell lung cancer receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy

BACKGROUND: This study aimed to develop and validate a novel nomogram to predict survival in advanced non-small cell lung cancer (NSCLC) receiving programmed cell death 1 (PD-1) inhibitor plus chemotherapy with or without antiangiogenic therapy. METHODS: A total of 271 patients with advanced NSCLC w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yahua, Lv, Chengliu, Lin, Mingqian, Hong, Yaping, Du, Bin, Yao, Na, Zhu, Yingjiao, Ji, Xiaohui, Li, Jiancheng, Lai, Jinhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663364/
https://www.ncbi.nlm.nih.gov/pubmed/38022521
http://dx.doi.org/10.3389/fimmu.2023.1297188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663364/
https://www.ncbi.nlm.nih.gov/pubmed/38022521
http://dx.doi.org/10.3389/fimmu.2023.1297188

Ejemplares similares